Introduction to Neuromorphic Computing

Neuromorphic computing is an emerging field that has the potential to drastically influence every human’s life within the next decades. Neuromorphic computing explores the computing process of the brain and attempts to replicate it onto modern electronics. It offers improvements on current computer architecture, the von Neumann architecture, and will lead to more efficient computing, easier development of machine learning, and further integration of electronics and biology

Adhesive Methods for Scaffold-aided Repair of Spina Bifida

Spina bifida aperta is a serious birth defect involving the protrusion of the spinal cord outside the spine that can lead to partial paralysis, inability to control the urinary tract, and often death, before or after birth. On average, medical treatment related to spina bifida costs the United States $1,176,000,000 each year. Advancements in existing treatment options, namely fetal surgery, can greatly decrease neurological injury and related costs, but can also lead to birth complications and have lasting effects on both the mother and child. The application of tissue scaffolds to aid closure of the gap left after fetal correction have been in development, but advancements in adhesive methods for the scaffolds are needed to decrease surgery time and increase deformity coverage. This study compares strengths of different adhesive methods in a simulated amniotic fluid environment through peel tests and determines the viability in vitro of a lab-produced collagen patch as a scaffold to cover the spina bifida defect

Hydro-chemical characteristics and groundwater quality evaluation in south-western region of Bangladesh: A GIS-based approach and multivariate analyses

The study focuses on the chemistry of groundwater and if it is suitable for drinking and for use in agriculture using water quality indices, GIS mapping, and multivariate analyses in Sharsa Upazila, Jashore district, Bangladesh. In this study, the concentration of NH4+, K+, Ca2+, EC, Turbidity overstep BDWS drinking standards in 69 %, 14 %, 100 %, 40 % (WHO), 73 % of samples respectively. The value of Water Quality Indices (WQI) results inferred that the maximum specimen was held good quality for drinking uses, and the values distributed central eastern part to the south-eastern part were good quality water in the selected studied area. The study area's PH, EC, SAR, Na (%), TH, and NO3− values were mapped using GIS tools to show their spatial distribution. The cluster and correlation matrix analyses are used to validate for Principle Component Analysis (PCA). The five PCA results exhibited that the presence of EC, turbidity, K+, SO42− and NO3− was significant and was caused by both geogenic (rock weathering and cation exchange) and anthropogenic (agrochemicals, animal feedback) factor. According to the hydro-geochemical data, the maximum number of samples is of the Ca–Mg–HCO3–Cl type and is dominated by rocks. The irrigation water indices like MH, KR, SAR, and %Na indicate show high-quality groundwater for irrigation purposes. Most of the samples were satisfactory and compiled with WHO and Bangladeshi criteria for standard drinking water guideline values

An evaluation of 4 commercial assays for the detection of SARS-CoV-2 antibodies in a predominantly mildly symptomatic low prevalence Australian population

A total of 1080 individual patient samples (158 positive serology samples from confirmed, predominantly mildly symptomatic COVID-19 patients and 922 serology negative including 496 collected pre-COVID) from four states in Australia were analysed on four commercial SARS-CoV-2 serological assays targeting antibodies to different antigens (Roche Elecsys and Abbott Architect: nucleocapsid; Diasorin Liaison and Euroimmun: spike). A subset was compared to immunofluorescent antibody (IFA) and micro-neutralisation. Sensitivity and specificity of the Roche (n = 1033), Abbott (n = 806), Diasorin (n = 1034) and Euroimmun (n = 175) were 93.7 %/99.5 %, 90.2 %/99.4 %, 88.6 %/98.6 % and 91.3 %/98.8 %, respectively. ROC analysis with specificity held at 99 % increased the sensitivity for the Roche and Abbott assays from 93.7% to 98.7% (cut-off 0.21) and 90.2 % to 94.0 % (cut-off 0.91), respectively. Overall seropositivity of samples increased from a maximum of 23 % for samples 0-7 days-post-onset of symptoms (dpos), to 61 % from samples 8-14dpos and 93 % from those >14dpos. IFA and microneutralisation values correlated best with assays targeting antibodies to spike protein with values >80 AU/mL on the Diasorin assay associated with neutralising antibody. Detectable antibody was present in 22/23 (96 %), 20/23 (87 %), 15/23 (65 %) and 9/22 (41 %) patients with samples >180dpos on the Roche, Diasorin, Abbott and microneutralisation assays respectively. Given the low prevalence in this community, two-step algorithms on initial positive results saw an increase in the positive predictive value (PPV) of positive samples (39 %-65 % to ≥98 %) for all combinations. Similarly accuracy increased from a range of 98.5 %-99.4 % to ≥99.8 % assuming a 1 % seroprevalence. Negative predictive value (NPV) was high (≥99.8 %) regardless of which assay was used initially

SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity

Respiratory tract infection with SARS-CoV-2 results in varying immunopathology underlying COVID-19. We examine cellular, humoral and cytokine responses covering 382 immune components in longitudinal blood and respiratory samples from hospitalized COVID-19 patients. SARS-CoV-2-specific IgM, IgG, IgA are detected in respiratory tract and blood, however, receptor-binding domain (RBD)-specific IgM and IgG seroconversion is enhanced in respiratory specimens. SARS-CoV-2 neutralization activity in respiratory samples correlates with RBD-specific IgM and IgG levels. Cytokines/chemokines vary between respiratory samples and plasma, indicating that inflammation should be assessed in respiratory specimens to understand immunopathology. IFN-α2 and IL-12p70 in endotracheal aspirate and neutralization in sputum negatively correlate with duration of hospital stay. Diverse immune subsets are detected in respiratory samples, dominated by neutrophils. Importantly, dexamethasone treatment does not affect humoral responses in blood of COVID-19 patients. Our study unveils differential immune responses between respiratory samples and blood, and shows how drug therapy affects immune responses during COVID-19

Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: A randomized clinical trial

IMPORTANCE Extended-spectrum β-lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in Escherichia coli and Klebsiella pneumoniae. Significant infections caused by these strains are usually treated with carbapenems, potentially selecting for carbapenem resistance. Piperacillin-tazobactam may be an effective “carbapenem-sparing” option to treat extended-spectrum β-lactamase producers. OBJECTIVES To determine whether definitive therapy with piperacillin-tazobactam is noninferior to meropenem (a carbapenem) in patients with bloodstream infection caused by ceftriaxone-nonsusceptible E coli or K pneumoniae. DESIGN, SETTING, AND PARTICIPANTS Noninferiority, parallel group, randomized clinical trial included hospitalized patients enrolled from 26 sites in 9 countries from February 2014 to July 2017. Adult patients were eligible if they had at least 1 positive blood culture with E coli or Klebsiella spp testing nonsusceptible to ceftriaxone but susceptible to piperacillin-tazobactam. Of 1646 patients screened, 391 were included in the study. INTERVENTIONS Patients were randomly assigned 1:1 to intravenous piperacillin-tazobactam, 4.5 g, every 6 hours (n = 188 participants) or meropenem, 1 g, every 8 hours (n = 191 participants) for a minimum of 4 days, up to a maximum of 14 days, with the total duration determined by the treating clinician. MAIN OUTCOMES AND MEASURES The primary outcome was all-cause mortality at 30 days after randomization. A noninferiority margin of 5% was used. RESULTS Among 379 patients (mean age, 66.5 years; 47.8% women) who were randomized appropriately, received at least 1 dose of study drug, and were included in the primary analysis population, 378 (99.7%) completed the trial and were assessed for the primary outcome. A total of 23 of 187 patients (12.3%) randomized to piperacillin-tazobactam met the primary outcome of mortality at 30 days compared with 7 of 191 (3.7%) randomized to meropenem (risk difference, 8.6% [1-sided 97.5% CI, − to 14.5%]; P = .90 for noninferiority). Effects were consistent in an analysis of the per-protocol population. Nonfatal serious adverse events occurred in 5 of 188 patients (2.7%) in the piperacillin-tazobactam group and 3 of 191 (1.6%) in the meropenem group. CONCLUSIONS AND RELEVANCE Among patients with E coli or K pneumoniae bloodstream infection and ceftriaxone resistance, definitive treatment with piperacillin-tazobactam compared with meropenem did not result in a noninferior 30-day mortality. These findings do not support use of piperacillin-tazobactam in this setting.</p